ACE-031 Protocol: How to Cycle It, Timing & What to Expect

Protocol snapshot

• Typical cycle length: 12 weeks is the closest clinical reference point, based on the Phase 2 trial design; community-reported cycles often run approximately 30 days with a 6 to 12 week off-cycle break
• Frequency: Once every 2 to 4 weeks, driven by the 10 to 15 day half-life; daily or twice-weekly dosing is pharmacologically contraindicated
• Common delivery routes: Subcutaneous injection only (the sole route in both clinical and community use)
• Key timing notes: The compound remains pharmacologically active for approximately 25 days after the final injection; off-cycle planning must account for this extended active window

Who This Protocol Is For

ACE-031 draws interest from a specific and narrowly defined group: experienced researchers and self-experimenters focused on skeletal muscle hypertrophy who have already worked through conventional and well-studied peptides and are exploring what lies at the edge of myostatin inhibition research. The protocol is nothing like the daily or twice-daily schedules that define most peptide use. Most use sits with experienced researchers who have already run well-studied compounds and are deliberately stepping into less-mapped territory.

The goals most commonly associated with ACE-031 research are lean mass accretion and functional strength, based on clinical data showing measurable increases in muscle volume within 29 days of a single injection. Some interest also comes from researchers studying muscle-wasting conditions, following the compound's origins in Duchenne Muscular Dystrophy trial work. The clinical data on bone metabolism biomarker changes has generated secondary interest in metabolic and bone health contexts, though this remains secondary to the hypertrophy signal.

Experience level matters significantly here. The infrequent dosing schedule, the need to recognize and monitor specific adverse signals, and the absence of any validated long-term cycling protocol all require familiarity with how research compounds are run, how their half-lives shape a schedule, and how to assess individual response over a long active window.

Delivery-method preference is not a variable. Subcutaneous injection (an injection into the fatty tissue just beneath the skin) is the only route in any clinical or community data, and that shapes the protocol from the start. There is no oral, nasal, or sublingual data for this compound.

How Is an ACE-031 Cycle Structured?

An ACE-031 cycle looks structurally different from nearly every other peptide protocol. The reason is pharmacokinetic: with a mean half-life of ten to fifteen days, the compound stays active in the body long after each injection, which means frequent dosing causes accumulation rather than stable levels. The entire cycle shape follows from that pharmacology.

The closest thing to a clinical cycle reference comes from the Phase 2 Duchenne Muscular Dystrophy trial, which used a twelve-week structure with injections spaced once every four weeks, for a total of three injections across the cycle. Community-reported cycles tend to run shorter, often approximately thirty days of active use, though the compound continues working for roughly twenty-five days after the final injection, so the functional window of effect extends well beyond the last dose date.

The three phases that define most peptide protocols (loading, maintenance, off-cycle) do not map cleanly onto ACE-031. There is no established loading phase and no studied maintenance phase. The cycle structure here is better understood as: infrequent injections during the active period, followed by an extended off-cycle break that accounts for continued activity post-injection. The detail on that off-cycle period is in its own section. Because no validated human cycling protocol was completed before the clinical program ended, the cycle shapes above reflect the best available clinical and community reference data, not an approved framework.

How Your Dose Is Determined

What moves an ACE-031 dose:

• Your goal: Goals oriented toward measurable hypertrophy sit toward the higher end of the range seen in Phase 1 data, while early safety work started at levels far below those producing visible effects. There is no consensus on a maintenance-level dose because no maintenance phase was ever evaluated, and goals related to metabolic or bone health sit in a different part of the range from aggressive hypertrophy targets.
• Experience level: The clinical ascending-dose design began at levels that produced no visible effect and moved upward only when tolerated. That principle reflects the non-selective mechanism and the vascular risk profile, making a conservative start and careful evaluation of individual response more important here than with most compounds.
• Delivery route: Subcutaneous injection is the only route with any data, so the route is fixed and does not create a dosing variable the way it does with compounds that have multiple delivery options.
• Individual response: Two people pursuing the same goal can have meaningfully different baseline vascular sensitivity to BMP9 and BMP10 (signaling proteins essential for blood vessel maintenance) blockade. Individual response here covers not only efficacy but also where the line between tolerated and problematic sits for that specific person.

Because the trial program was terminated before a full dosing protocol was established, the factors above interact in ways that cannot be reduced to a simple rule. The dose depends on the goal, on careful reading of individual response from the earliest exposures, and on the delivery schedule dictated by the compound's pharmacokinetics. There is no single dose that fits everyone, which is exactly what the app personalizes.

Your dose should not be a guess. The MyPeptidePal Protocol Creator takes your goal type, your injection frequency, and your individual response tolerance and builds your ACE-031 protocol: your dose, your cycle, and your timing.

Get your protocol at mypeptidepal.ai

How Often Do You Take ACE-031?

The answer is unlike the answer for most peptides, and the pharmacokinetics are the reason. ACE-031 has a mean half-life of ten to fifteen days, meaning each injection stays biologically active for an extended period. Dosing more frequently than every two to four weeks allows the compound to accumulate rather than cycle through. Daily dosing, which is standard for many short-half-life peptides, would cause toxic accumulation with ACE-031. Twice-weekly protocols that appear in some online sources directly contradict what the clinical pharmacokinetic data supports.

In clinical trials, the schedule was a single subcutaneous injection once every four weeks, a direct reflection of the half-life rather than an arbitrary choice. Community protocols sometimes push toward once every two weeks, which sits within a range some researchers consider pharmacologically plausible given the half-life data, but this remains outside any validated clinical framework.

Timing within the dosing day, such as morning versus evening, is not a meaningful variable for ACE-031 the way it is for peptides that need to sync with circadian rhythms or pulsatile hormone release. What matters is the interval between doses, not the clock time of administration. Because the compound remains active for approximately twenty-five days after the final injection, planning the end of a cycle requires thinking not just about when the last injection happens but about when the biological effect actually winds down.

Loading and Maintenance Phases

ACE-031 does not use a loading and maintenance phase structure in the way most peptides do. No established loading protocol exists, and no maintenance phase was ever evaluated in human trials, because the clinical program ended before full protocol development could occur.

What the trial record does provide is a dose-escalation approach. In the Phase 1 single ascending-dose study, participants received a single injection at a given level and were monitored for twenty-nine days before the next cohort received a higher level. That design was built for safety characterization, not for optimizing a cycle, but it carries a practical implication: starting conservatively and assessing individual response before any escalation reflects the compound's risk profile.

In the Phase 2 Duchenne trial, injections were given at consistent levels once every four weeks, with no distinct front-loaded higher phase at the start. With a half-life of ten to fifteen days, the compound reaches meaningful active levels from a single injection without a separate loading strategy. There is no pharmacokinetic rationale for a higher opening dose designed to accelerate time to steady-state.

In practice, what passes for a cycle with ACE-031 is a short series of infrequent injections followed by an extended clearance period. The phased cycling concept does not map onto this compound the way it does for daily-dosed peptides. The structure is simpler and driven entirely by the pharmacokinetics.

Off-Cycle Considerations

Off-cycle planning for ACE-031 requires a different frame than most peptides because the compound does not clear quickly. With a half-life of ten to fifteen days, it remains pharmacologically active for approximately twenty-five days after the final injection. The off-cycle period effectively begins when the compound has cleared to a level where its biological effects have meaningfully wound down, not at the moment of the last dose.

Community consensus on minimum off-cycle length generally lands at six weeks, with many experienced users extending to six to twelve weeks. The rationale is not receptor sensitivity or tolerance in the typical sense. It is primarily about giving the body time to clear the compound and allowing monitoring of the vascular adverse event signals that concern researchers most closely following this compound. Nosebleeds, gum bleeding, and telangiectasia (tiny dilated blood vessels visible on the skin surface) resolved upon discontinuation in Phase 1 data, but the mechanism that causes them persists through the extended active window and warrants monitoring throughout it.

Some users have advocated for assessing vascular health markers before initiating a subsequent cycle rather than running on a fixed schedule. That approach reflects the broader principle that the off-cycle here functions as a monitoring window for a compound with known vascular liabilities, not a routine rest period.

No clinical data exists on what an optimal off-cycle length looks like for ACE-031, because no repeat-cycle human data was generated. The guidance above reflects community protocols and the pharmacokinetic rationale.

What to Expect Week by Week

• Days 1 to 7: No visible physical changes. The compound is distributing through the system after injection. Injection site reactions, including local pain and redness, are commonly reported during this early window and can persist for several days.
• Days 7 to 14: The compound approaches more active levels as distribution completes. Some users report unusual sensations near the injection site or in surrounding limbs. No visible hypertrophy changes at this stage.
• Day 29: This is the most reported timepoint in the human clinical data. In one Phase 1 cohort of postmenopausal women receiving a single high-level injection, the data showed a 3.3% increase in total lean body mass measured by DXA (a body-composition scan) and a 5.1% increase in thigh muscle volume measured by MRI within twenty-nine days, without changes to exercise or diet. These are the most concrete single-study reference points the literature provides, not established population benchmarks.
• Days 25 to 45: The compound remains active through this window due to the half-life, meaning effects continue past the injection date. In the Phase 2 DMD trial, the ACE-031 group maintained walking distance on a six-minute walk test while the placebo group declined over the same period.

A well-run cycle, maintained at a consistent schedule with careful monitoring of adverse signals, commonly tracks toward the pattern the clinical data describes: the first measurable changes in body composition emerging around the end of the first month and continuing through the active window. The functional strength and volume gains seen in clinical data emerged within a single dosing interval, which is a faster observable timeline than most muscle-focused compounds. Individual results will vary by goal, individual response, and schedule consistency. The timeline above reflects the clinical and community data available, not a guarantee of outcome.

Common Protocol Mistakes

Dosing too frequently. The most common mistake is running ACE-031 on a daily or twice-weekly schedule borrowed from other peptides. With a half-life of ten to fifteen days, frequent dosing causes accumulation rather than stable active levels. The clinical schedule was once every two to four weeks. Daily dosing is not a more aggressive version of the correct protocol; it is a pharmacologically different and dangerous one.

Assuming selectivity. ACE-031 is sometimes described as a "myostatin inhibitor" in a way that implies it acts like a targeted off switch for one molecule. It does not. It binds and neutralizes a range of TGF-beta family ligands (a class of signaling proteins that regulate muscle growth, bone density, and blood vessel function), including BMP9 and BMP10 (two proteins critical for vascular homeostasis, meaning the stable maintenance of healthy blood vessels). The nosebleeds, gum bleeding, and telangiectasia that terminated the clinical program were a direct consequence of this mechanism, not incidental side effects. Researchers who approach this compound expecting selective muscle-building pharmacology without vascular implications are misreading what it does.

Reconstituting and storing. ACE-031 has poor stability after reconstitution. Preparing a vial and storing the solution for later use leads to degradation and potency loss. Immediate use of the full vial after reconstitution is the approach reflected in available handling guidance. Storing reconstituted ACE-031 is a handling error that affects both efficacy and the meaningfulness of any observed response.

Minimizing the vascular signals. Nosebleeds and gum bleeding during a cycle are not a nuisance to push through. They are the specific adverse events that caused an entire clinical development program to be terminated. Forum discussions consistently show the same signals appearing in self-experimenting users. Anyone who notices these signals and continues dosing is disregarding the exact safety data that ended formal development.

Skipping off-cycle planning. Because the compound remains active for approximately twenty-five days after the final injection, starting a new cycle before adequate clearance and monitoring time has passed means running the compound on an effectively continuous basis while treating it as cycled. A minimum six-week off-cycle break, with attention to any persisting vascular symptoms through the extended active window, reflects both the pharmacokinetics and the safety profile.

ACE-031 is not FDA-approved for human use and is a prohibited substance under WADA for competitive athletes. Its clinical development was officially terminated in May 2013, and no country has approved it for medical use.

Frequently Asked Questions

How long is a typical ACE-031 cycle?

The closest clinical reference is the twelve-week Phase 2 trial design, which used three injections spaced once every four weeks. Community-reported cycles often run approximately thirty days of active dosing, though the compound continues to be pharmacologically active for roughly twenty-five days after the final injection. Your specific cycle length is personalized in the MyPeptidePal Protocol Creator.

How often do you take ACE-031?

The clinical schedule was once every four weeks, reflecting the compound's ten to fifteen day half-life. Some community protocols use a once every two weeks frequency, which is the more aggressive end of what the pharmacokinetics can plausibly support. Daily or twice-weekly dosing is inconsistent with the half-life and risks accumulation.

Does ACE-031 need a loading phase?

No. The clinical trial data shows no distinct loading phase was used or evaluated. Because the half-life is ten to fifteen days, a single injection produces active levels without a separate front-loading strategy. Injections were kept consistent across the Phase 2 trial rather than starting higher to build initial levels.

Do you need to cycle off ACE-031?

Yes, and the off-cycle period requires more planning than most compounds. The drug remains active for approximately twenty-five days after the final injection, so the off-cycle window effectively begins at that point rather than at the last dose date. Community consensus on minimum off-cycle length is six weeks, with many users extending to six to twelve weeks to allow adequate monitoring of vascular adverse event signals.

What are the primary safety signals to watch during an ACE-031 cycle?

The primary signals seen in clinical trials were nosebleeds, gum bleeding, and telangiectasia (tiny dilated blood vessels visible on the skin surface). These resulted from blockade of BMP9 and BMP10, disrupting vascular homeostasis (the body's ability to maintain stable, healthy blood vessels), and were severe enough to halt the clinical program. Forum data shows self-experimenting users reporting the same signals. These are not minor side effects to monitor passively; they are the specific reason formal development ended.

Is ACE-031 the same as a selective myostatin inhibitor?

No. ACE-031 acts as a decoy receptor for Activin Receptor Type IIB (a cell-surface protein that normally receives signals telling muscle to stop growing), binding and neutralizing myostatin plus a broader set of TGF-beta family ligands including Activin A, Activin B, BMP9, and BMP10. The non-selectivity is what caused the vascular adverse events and is why more selective myostatin inhibitor approaches have been pursued since the program ended.

Disclaimer

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world protocols for ACE-031 in one place.